Innovent Biologics, Inc.
Innovent Biologics, Inc. (IVBXF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ivbxf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Innovent Biologics, Inc. (IVBXF) measures how much investors pay for each dollar of the company's trailing earnings. IVBXF's current PE ratio of 132.41x is calculated by dividing its stock price of $9.10 by its TTM earnings per share of $0.48. −8.2% discount vs 5Y avg 144.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Innovent Biologics, Inc.You IVBXF | $15.8B | 132.41x | +421.8% | $0.48 |
 Astellas Pharma Inc. ALPMF | $25.9B | 15.65x | -38.3% | $163.79 |
 Astellas Pharma Inc. ALPMY | $24.2B | 14.92x | -41.2% | $172.58 |
 bioMérieux S.A. BMXXY | $9.9B | 33.13x | +30.6% | $0.32 |
 Grifols, S.A. GIKLY | $14.2B | 18.68x | -26.4% | $0.28 |
 Genmab A/S GNMSF | $15.3B | 19.58x | -22.9% | $16.04 |
 Sino Biopharmaceutical Limited SBHMY | $11.6B | 50.31x | +98.3% | $2.53 |
Industry Average 6 peers with valid PE | — | 25.38x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 144.30x | $0.47 | — | |
2024-12-31 FY2024 | — | $-0.06 | — | |
2023-12-31 FY2023 | — | $-0.66 | — | |
2022-12-31 FY2022 | — | $-1.46 | — | |
2021-12-31 FY2021 | — | $-1.88 | — | |
2020-12-31 FY2020 | — | $-0.74 | — | |
2019-12-31 FY2019 | — | $-1.46 | — | |
2018-12-31 FY2018 | — | $-17.24 | — | |
2017-12-31 FY2017 | — | $-0.50 | — | |
2016-12-31 FY2016 | — | $-0.45 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Innovent Biologics, Inc. (IVBXF) measures how much investors pay for each dollar of the company's trailing earnings. IVBXF's current PE ratio of 132.41x is calculated by dividing its stock price of $9.10 by its TTM earnings per share of $0.48.
Frequently asked questions
IVBXF pe ratio · 6 questionsIVBXF's current PE ratio is 132.41x as of 2026-06-09, based on a stock price of $9.10 and TTM EPS of $0.48. Data sourced from Financial Modeling Prep via IVBXF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Innovent Biologics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09